236 related articles for article (PubMed ID: 23652942)
1. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
[No Abstract] [Full Text] [Related]
2. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia.
Prabhash K; Biswas G; Prasad N; Karant N; Sastry PS; Parikh PM
Indian J Dermatol Venereol Leprol; 2006; 72(1):63-4. PubMed ID: 16481719
[No Abstract] [Full Text] [Related]
3. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
Lau YM; Lam YK; Leung KH; Lin SY
Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
[No Abstract] [Full Text] [Related]
4. Vocal fold hemorrhage in a CML patient after Glivec treatment.
Shim HS; Woo SH
Acta Oncol; 2013 May; 52(4):866-8. PubMed ID: 23153030
[No Abstract] [Full Text] [Related]
5. A patient of chronic myelogenous leukemia developing painful rash on feet.
Kumar P; Das NK; Sil A; Chakrabarti P
J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
[No Abstract] [Full Text] [Related]
6. Multiple eruptive dermatofibromas related to imatinib treatment.
Llamas-Velasco M; Fraga J; Solano-López GE; Steegmann JL; García Diez A; Requena L
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):979-81. PubMed ID: 24321053
[No Abstract] [Full Text] [Related]
7. [Standard therapy for chronic myelogenous leukemia].
Kimura S
Rinsho Ketsueki; 2012 Oct; 53(10):1571-80. PubMed ID: 23037729
[No Abstract] [Full Text] [Related]
8. Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia.
Deguchi N; Kawamura T; Shimizu A; Kitamura R; Yanagi M; Shibagaki N; Matsue H; Shimada S
Br J Dermatol; 2006 Jun; 154(6):1216-8. PubMed ID: 16704666
[No Abstract] [Full Text] [Related]
9. Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib.
Steele JC; Triantafyllou A; Rajlawat BP; Field EA
Clin Exp Dermatol; 2012 Jun; 37(4):432-3. PubMed ID: 22420895
[No Abstract] [Full Text] [Related]
10. Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.
Khoo TL; Catalano A; Supple S; Chong L; Yeoh SC; Yeung S; Iland H
Leuk Lymphoma; 2013 Jan; 54(1):186-8. PubMed ID: 22712835
[No Abstract] [Full Text] [Related]
11. Imatinib-associated hyperpigmentation, a side effect that should be recognized.
Mcpherson T; Sherman V; Turner R
J Eur Acad Dermatol Venereol; 2009 Jan; 23(1):82-3. PubMed ID: 18384557
[No Abstract] [Full Text] [Related]
12. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
[No Abstract] [Full Text] [Related]
13. Imatinib: a designer drug, another cutaneous complication.
Dickens E; Lewis F; Bienz N
Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
[TBL] [Abstract][Full Text] [Related]
14. Imatinib-associated melanosis of the palate.
Roeker LE; Wolanskyj AP
Am J Hematol; 2014 May; 89(5):564. PubMed ID: 24030927
[No Abstract] [Full Text] [Related]
15. Pseudoporphyria induced by imatinib mesylate.
Pérez NO; Esturo SV; Viladomiu Edel A; Moreno AJ; Valls AT
Int J Dermatol; 2014 Feb; 53(2):e143-4. PubMed ID: 23451912
[No Abstract] [Full Text] [Related]
16. Imatinib mesylate-induced neutrophilic folliculitis in a teenager.
García-Romero MT; Durán-McKinster C; de Ocariz MS; Carrasco-Daza D; Palacios-López C; Orozco-Covarrubias L; Ruiz-Maldonado R
Int J Dermatol; 2012 Dec; 51(12):1529-30. PubMed ID: 22486540
[No Abstract] [Full Text] [Related]
17. [Management of chronic myeloid leukemia by imatinib].
Kizaki M
Rinsho Ketsueki; 2010 Oct; 51(10):1377-85. PubMed ID: 20962470
[No Abstract] [Full Text] [Related]
18. [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia].
Shimizu K; Kuroda H; Kida M; Watanabe H; Shirao S; Akiyama T; Fujimi A; Tanaka I; Sato T; Matsunaga T; Niitsu Y
Rinsho Ketsueki; 2005 Oct; 46(10):1152-5. PubMed ID: 16440780
[TBL] [Abstract][Full Text] [Related]
19. [Chronic myeloid leukemia treatment and human immunodeficiency virus infection].
Campillo-Recio D; Perez-Rodriguez L; Yebra E; Cervero-Jimenez M
Rev Clin Esp (Barc); 2014 May; 214(4):231-2. PubMed ID: 24564991
[No Abstract] [Full Text] [Related]
20. Cardiotoxicity of imatinib: At the heart of the problem.
Tiribelli M; Medeot M
Leuk Res; 2011 Jan; 35(1):36-7. PubMed ID: 20970188
[No Abstract] [Full Text] [Related]
[Next] [New Search]
